Recro Pharma, Inc. (Nasdaq: REPH) announced that the first patient was dosed in the pivotal Phase III clinical trial evaluating ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE